Holen Sie sich die Stockscreener-App
0.1412
6.26%
-0.009
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan
CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et
Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm
Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan
Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK
Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks
Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart
Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com
Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan
Calidi Biotherapeutics appoints Corsee Sanders to board By Investing.com - Investing.com UK
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times
Press Release: Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Moomoo
Calidi adds former Genentech and Roche executive to board - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Calidi Biotherapeutics, Inc. Files Form 8-K with SEC: Key Corporate Details, Stock Info & NYSE American Listing - Minichart
CLDI News | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics Stockholders Approve Key Governance Measures - TipRanks
Calidi Biotherapeutics (CLDI) stockholders back all proposals at 2026 annual meeting - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Calidi Biotherapeutics Inc (CLDI) Institutional Confidence - TradingKey
Calidi Biotherapeutics Inc (CLDI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Calidi receives pre-IND feedback from FDA on CLD-401 - BioWorld News
Calidi Biotherapeutics Receives Positive Feedback From FDA for CLD-401 Pre-IND Application - marketscreener.com
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewswire
FDA feedback sets path for Calidi CLD-401 oncolytic virus trial - Stock Titan
CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Chart - ChartMill
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAdjusted Earnings Analysis - lwvtexas.org
CLDI Q4 2025 Earnings: Narrower Loss Signals Progress in Clinical PipelineProfit Inflection Point - newsline.com
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - ACCESS Newswire
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - GlobeNewswire
Calidi Biotherapeutics (CLDI) Edges Lower, Testing Key Support at $0.16Regression Channel - newsline.com
CLDI Q4 2025 Earnings: Significant EPS Beat Highlights Progress in Oncolytic Virus Therapy DevelopmentFull Year Guidance - newsline.com
Calidi Biotherapeutics (CLDI) Hovers Near Key Support Amid Continued Selling PressureShakeout Pattern - newsline.com
CLDI Q4 2025 Earnings: Narrowing Losses Exceed Expectations Amid Continued Pipeline DevelopmentMargin Expansion Trends - dars.gov.et
Calidi Biotherapeutics, Inc. Files Form 8-K Disclosing Amended and Restated Warrant Agreement – Key Details and XBRL Data - Minichart
Calidi Biotherapeutics Amends Warrant in Private Placement - TipRanks
Calidi Biotherapeutics Amends Warrant for 17.4M Shares at $0.23; Stockholder OK Required - TradingView
Calidi (NYSE: CLDI) extends vesting and adjusts major warrant terms - Stock Titan
Number of shareholders of Calidi Biotherapeutics, Inc. – AMEX:CLDI - TradingView
CLDICalidi Biotherapeutics Inc Stock Price and Quote - Finviz
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - Weekly Voice
Tumor-targeting virotherapy from Calidi to appear at 2026 ASCO - Stock Titan
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Surprises, Stock DeclinesEarnings Season Review - newsline.com
Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Despite Stock Decline - Newser
Calidi Biotherapeutics Provides Required NYSE American Disclosure - The Manila Times
Calidi Biotherapeutics discloses NYSE-required audit note on going concern status in 2025 financial report. - Pluang
Calidi Biotherapeutics, Inc. Issues Financial Statement Audit Report Highlighting Going Concern Assumption - Quiver Quantitative
Biotech Calidi’s 2025 audit report includes 'going concern' note - Stock Titan
Armistice Capital (CLDI) reports 1.11M shares, 9.99% ownership - Stock Titan
Calidi Highlights Q1 Results and RedTail Platform Progress - TipRanks
1.16%
0.48%
Kapitalisierung:
|
Volumen (24h):